Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach

Gizem Yeğen; Buket Aksu; Erdal Cevher

Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach

Abstract

Orally Disintegrating Tablets (ODTs) are solid dosage forms that rapidly disintegrate or dissolve to release the drug upon contact with saliva in the mouth. As these tablets require special attention during formulation design, it is necessary to use advanced control and formulation design techniques to increase the quality. Quality by Design (QbD) was defined as an approach including better scientific understanding of critical process and product attributes, designing controls and tests based on scientific understanding limits during development stage and used to work in an environment for continuous improvement of information obtained during the product lifecycle. The aim of the study was to develop an ODT formulation containing Metoprolol tartrate with appropriate features via QbD approach with the help of artificial intelligence programs to enlight the multivariate relations between critical parameters and quality attributes of on final product and to obtain an optimum formulation. Physical and chemical tests were conducted on tablets prepared by direct compression according to the designated formulation and process variables. Then, experimental data was evaluated with modeling programs use artificial intelligence technique, FormRules V3.32 to understand the relationship between independent input variables and the critical quality attributes; later with INForm V5.1 for optimization. The optimized formula was prepared and according to test results tablets shows compliance with the pharmacopoeia limits. The adoption of QbD approach and usage of artificial intelligence programs has increased the efficiency of the formulation development process with better understanding of the product and process.

Keywords

References

[1] Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery – a review. Pharm Sci Technol Today. 2000; 3(4): 138-145.
[2] Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharm J. 2016; 24(5): 537-546.
[3] Liandong H, Deliang G, Qiaofeng H, Hailei Z, Xun Y. A novel approach to formulate and optimize orally disintegrating tablets of Bambuterol hydrochloride. Pharm Anal Acta. 2013; 4(3): 216. Research Article [4] Rahane RD, Rachh PR. A Review on Fast Dissolving Tablet. J Drug Deliv & Ther. 2018; 8(5):50-55.
[5] Bandari S, Mittapalli RK, Gannu R. Orodispersible Tablets: An Overview. Asian J Pharm. 2008; 2(1): 2-11.
[6] Allam A, Fetih G. Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate. Drug Des Dev Ther. 2016; 10: 2421–2433.
[7] Aksu B, Paradkar A, DeMatas M, Ozgen O, Guneri T, York P. Quality by Design Approach: Application of Artificial Intelligence Techniques of Tablets Manufactured by Direct Compression. AAPS PharmSciTech. 2012; 13(4): 1138-146.
[8] ICH Guideline Pharmaceutical Quality System (PQS) Q 10, 2008. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf (accessed on 18 January 2021).
[9] ICH Guideline Development and manufacture of drug substances Q11, 2012. https://database.ich.org/sites/default/files/Q11%20Guideline.pdf (accessed on 18 January 2021).

[10] Güncan G, Yegen G, Mesut B, Aksu B, Ozsoy Y. Formulation design of the oral disintegrating tablets including alfuzosin hydrochloride with risk evaluation via quality by design. Acta Pharm Sci. 2017; 55(2): 57-76.
[11] Colbourn EA, Rowe CR. Neural computing and formulation optimization. In: Swarbrick J (Ed). Encyclopedia of Pharmaceutical Technology. Informa Healthcare USA, Inc, New York, 2007, pp.2399–412.
[12] Colbourn EA, Roskilly SJ, Rowe RC, York P. Modelling formulations using gene expression programming – A comparative analysis with artificial neural networks. Eur J Pharm Sci. 2011; 44(3): 366–374.
[13] Powder flow analyser help file. Stable Micro Systems, 2007. https://www.stablemicrosystems.com/ManualRequest.html (accessed on 31 December, 2020).
[14] Aksu B, Yegen G, Purisa S, Cevher E, Ozsoy Y. Optimisation of Ondansetron orally disintegrating tablets using artificial neural networks. Trop J Pharm Res. 2014; 13(9): 1374 -1383.
[15] Aksu B, Paradkar A, DeMatas M, Ozgen O, Guneri T, York P. A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation. Pharm Dev & Technol. 2013; 18(1): 236-245.
[16] Yurdasiper A, Aksu B, Okur N, Gokce E. An Optimization Study on Solid Lipid Nanoparticles Using Artificial Neural Network. Lat Am J Pharm. 2017; 36(1): 115-121.
[17] Aksu, B., Coşkunmeriç, N., Yeğen, G., Özalp, Y. ve Üstündağ Okur, N. Quality by design approach for optimizing preparation and characterization of buccal film formulation with different polymers. Int J Pharm Res. 2019; 11(1): 1153-1160.
[18] Aksu B, Yegen G, Benefits of Computerized Technologies in Pharmaceutical Development with Quality by Design Approach. J Comput Eng Inf Technol. 2017; 6: 1.
[19] U.S. Food and Drug Administration. Quality by Design for ANDAs: An example for modified release dosage forms. Example QbD MR Tablet Module 3 Quality 3.2.P.2 Pharmaceutical Development, 2011. https://www.fda.gov/media/82834/download (accessed on 31 December, 2020).
[20] Franceschini F, Galetto M. A new approach for evaluation of risk priorities of failure modes in FMEA. Int J Prod Res. 2010; 39(13): 2991-3002.
[21] Mohammed AQ, Sunkari PK, Srinivas P, Roy AK. Quality by Design in Action 1: Controlling Critical Quality Attributes of an Active Pharmaceutical Ingredient. Org Process Res Dev. 2015; 19(11): 1634–1644.
[22] Morade VB, Daga VR, Malpure PR. Formulation and Evaluation of Mouth Dissolvıng Tablets of Zolmitriptan. Asian J Pharm Tech. 2018; 8(2):43-51.
[23] U.S. Pharmacopeia Stage 6 Harmonization. Bulk Density and Tapped Density of Powders, 2015. https://www.usp.org/sites/default/files/usp/document/harmonization/gen-chapter/bulk_density.pdf (Accessed on 31 December, 2020). [24] Venkatalakshmi R, Jason Yoong J. Development and Evaluation of Mouth Dissolving Tablets using Natural Super Disintegrants. J Young Pharm. 2017; 9(3): 332-5.
[25] European pharmacopoeia. Pharmaceutical technical procedures: Disintegration of tablets and capsules, ed 7, EDQM, Council of Europe, Strasbourg, France, 2011; 254. http://uspbpep.com/ep50/2.9.1.%20disintegration%20of%20tablets%20and%20capsules.pdf (accessed on 31 December, 2020).Research Article
[26] U.S. Pharmacopeia Stage 6 Harmonization. Dissolution 1 material 1; a motor; a metallic drive shaft; and a cylindrical, 2011. https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/m99470-gc_711.pdf (accessed on 31 December, 2020).
[27] Cesme M, Tarinc D, Golcu A. Spectrophotometric determination of Metoprolol tartrate in pharmaceutical dosage forms on complex formation with Cu(II). Pharm. 2011; 4: 964-975.

Details

Primary Language

English

Subjects

Pharmaceutical Delivery Technologies

Journal Section

Research Article

Authors

Gizem Yeğen ^*
Türkiye

Buket Aksu
Türkiye

Erdal Cevher
Türkiye

Publication Date

June 28, 2025

Submission Date

March 23, 2021

Acceptance Date

July 22, 2021

Published in Issue

Year 2021 Volume: 25 Number: 5

IZ

https://izlik.org/JA24SE77UH

Cite

RIS / Bibtex

APA

Yeğen, G., Aksu, B., & Cevher, E. (2025). Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach. Journal of Research in Pharmacy, 25(5), 728-737. https://izlik.org/JA24SE77UH

AMA

1.Yeğen G, Aksu B, Cevher E. Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach. J. Res. Pharm. 2025;25(5):728-737. https://izlik.org/JA24SE77UH

Chicago

Yeğen, Gizem, Buket Aksu, and Erdal Cevher. 2025. “Design of an Orally Disintegrating Tablet Formulation Containing Metoprolol Tartrate in the Context of Quality by Design Approach”. Journal of Research in Pharmacy 25 (5): 728-37. https://izlik.org/JA24SE77UH.

EndNote

Yeğen G, Aksu B, Cevher E (July 1, 2025) Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach. Journal of Research in Pharmacy 25 5 728–737.

IEEE

[1]G. Yeğen, B. Aksu, and E. Cevher, “Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach”, J. Res. Pharm., vol. 25, no. 5, pp. 728–737, July 2025, [Online]. Available: https://izlik.org/JA24SE77UH

ISNAD

Yeğen, Gizem - Aksu, Buket - Cevher, Erdal. “Design of an Orally Disintegrating Tablet Formulation Containing Metoprolol Tartrate in the Context of Quality by Design Approach”. Journal of Research in Pharmacy 25/5 (July 1, 2025): 728-737. https://izlik.org/JA24SE77UH.

JAMA

1.Yeğen G, Aksu B, Cevher E. Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach. J. Res. Pharm. 2025;25:728–737.

MLA

Yeğen, Gizem, et al. “Design of an Orally Disintegrating Tablet Formulation Containing Metoprolol Tartrate in the Context of Quality by Design Approach”. Journal of Research in Pharmacy, vol. 25, no. 5, July 2025, pp. 728-37, https://izlik.org/JA24SE77UH.

Vancouver

1.Gizem Yeğen, Buket Aksu, Erdal Cevher. Design of an orally disintegrating tablet formulation containing metoprolol tartrate in the context of quality by design approach. J. Res. Pharm. [Internet]. 2025 Jul. 1;25(5):728-37. Available from: https://izlik.org/JA24SE77UH